Business
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
HOUSTON, May 13, 2025--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2025.
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"HOUSTON, May 13, 2025--(BUSINESS WIRE)--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the quarter ended March 31, 2025.","length":342,"tagName":"p"},{"type":"text","content":"Recent Corporate Highlights","length":27,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Announced positive interim results of an investigator-initiated proof of concept open-label study with low-dose (LD) IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD)","length":203,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Published results of a study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA), Coya’s investigational biologic combination to suppress pro-inflammatory myeloid cells, enhance Treg suppressive function, and modulate T cell proliferation, in an in vitro system of human immune cells obtained from healthy donors. The study was published in NeuroImmune Pharmacology and Therapeutics","length":397,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Reported progress from an academic supported first-in-class Treg-derived Exosome program of its investigational regulatory T cell-derived exosome (Treg exosomes) platform intended for the treatment of systemic and neurodegenerative diseases driven by chronic inflammation","length":271,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer’s disease (AD)","length":218,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Announced expansion of pipeline - COYA 303 and COYA 301 - in combination with GLP-1 Receptor Agonist for treatment of inflammatory diseases and filing of new intellectual property portfolio for the combination.","length":210,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":1299,"olType":false},{"type":"text","content":"Upcoming Expected Catalysts for 2025","length":36,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"...